PF-Atlas › Treatments › iPSC-Derived AEC2 Transplant

iPSC-Derived AEC2 Transplant

Autologous iPSC-AEC2s replace depleted stem cell pool in prepared niche

Clinical research — In human clinical trials (Phase I–III). How PF-Atlas grades evidence.
Development stage
Preclinical
Evidence level
Level 3 (Preclinical)
Mechanism class
Autologous iPSC-AEC2s replace depleted stem cell pool in prepared niche
Timeline
5-10 years
Risk profile
High
Developer
BU/BMC
Key researchers
D. Kotton

Overview

Kotton lab gold standard iPSC-to-AEC2 protocol. Engraftment ~5% currently. Niche preparation is key.

How iPSC-Derived AEC2 Transplant fits into IPF treatment

iPSC-Derived AEC2 Transplant is classified as Level 3 (Preclinical) at the Preclinical stage. Explore how it compares to other options and where it sits in the development pipeline:

iPSC-Derived AEC2 Transplant drug profileAutologous iPSC-AEC2s replace depleted stem cell pool in prepared nicheClinical trialsDrug pipelineResearch

Other IPF treatments

Nerandomilast / JascaydInhaled Treprostinil / TyvasoAdmilparant / BMS-986278Rentosertib / ISM001-055AI Knowledge GraphuPAR-CAR-T Senolytic Immunotherapy
Medical disclaimer. This page summarizes published research and PF-Atlas model output about iPSC-Derived AEC2 Transplant for information only. It is not medical advice or a treatment recommendation. Drug availability, approval status and evidence change — verify with a pulmonologist and official sources (FDA, ClinicalTrials.gov) before any decision.